276730.KQ HanWool & Jeju, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
01:09
Apr 30
Apr 30
Alzinomics leads Korean cancer gene therapy.
Alzinomics has attracted the most attention in gene therapy. It is a rare Korean cancer gene-therapy case with human data, and it won a Lilly platform-related contract. Successful data also raise expectations that the Lilly-licensed genetic hearing loss indication could develop faster.
HIGH
About 276730.KQ Investor Commentary
Across the available history and selected sources, Buzzberg tracks 276730.KQ (HanWool & Jeju, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Kim Seon-ah.